Daza González M A, Fragío Arnold C, Fermín Rodríguez M, Checa R, Montoya A, Portero Fuentes M, Rupérez Noguer C, Martínez Subiela S, Cerón J J, Miró G
Small Animal Emergency and ICU Service, Hospital Clínico Veterinario Complutense, Veterinary Faculty, Universidad Complutense de Madrid (UCM), Avda Puerta Hierro sn., Madrid 28040, Spain.
Small Animal Emergency and ICU Service, Hospital Clínico Veterinario Complutense, Veterinary Faculty, Universidad Complutense de Madrid (UCM), Avda Puerta Hierro sn., Madrid 28040, Spain; Dept of Animal Medicine and Surgery, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Avda Puerta Hierro sn., Madrid 28040, Spain.
Vet J. 2019 Mar;245:22-28. doi: 10.1016/j.tvjl.2018.12.020. Epub 2018 Dec 19.
The objective of this study was to compare changes in serum concentrations of acute phase proteins (APPs) and paraoxanase (PON-1) in response to two treatments in dogs with leishmaniosis (CanL). For this purpose, 20 dogs with CanL were assigned to two treatment groups: antimonial plus allopurinol (Group G, n=12) and miltefosine plus allopurinol (Group M, n=8). Serum concentrations of PON-1 and APPs including C-reactive protein, haptoglobin (Hp), ferritin (Ft) and albumin were monitored over a period of 3 months after treatment. At the beginning of the study (day 0), most of the dogs had APP abnormalities. None of the variables differed significantly between groups in the first or subsequent visits. There was a significantly higher reduction in serum Ft in Group G than in Group M from day 0 to day 30 (P=0.0085), and also from day 0 to day 90 (P=0.0214). There was a higher increase in serum PON-1 in Group G than in than Group M from day 0 to day 30 (P=0.0039), and also from day 0 to day 90 (P=0.0404). This is the first report of APPs in dogs with natural clinical leishmaniosis treated with miltefosine. There was faster resolution of serum APP concentrations in dogs treated with antimonials (P<0.05).
本研究的目的是比较利什曼病(犬利什曼原虫病,CanL)犬在两种治疗方法下急性期蛋白(APPs)和对氧磷酶(PON-1)血清浓度的变化。为此,将20只患CanL的犬分为两个治疗组:锑剂加别嘌呤醇组(G组,n = 12)和米替福新加别嘌呤醇组(M组,n = 8)。在治疗后的3个月内监测PON-1和APPs的血清浓度,包括C反应蛋白、触珠蛋白(Hp)、铁蛋白(Ft)和白蛋白。在研究开始时(第0天),大多数犬存在APP异常。在首次或后续访视中,两组之间的任何变量均无显著差异。从第0天到第30天(P = 0.0085)以及从第0天到第90天(P = 0.0214),G组血清Ft的降低幅度显著高于M组。从第0天到第30天(P = 0.0039)以及从第0天到第90天(P = 0.0404),G组血清PON-1的升高幅度高于M组。这是关于用米替福新治疗自然临床型利什曼病犬的APPs的首次报告。用锑剂治疗的犬血清APP浓度的恢复更快(P<0.05)。